Aspen Pharmacare has received Health Canada approval for Aspen-Semaglutide, its generic version of Novo Nordisk’s diabetes medicine Ozempic. Aspen, Africa’s largest pharmaceutical manufacturer, announced that its Canadian subsidiary had secured the regulatory authorisation. The medicine has been approved for the management of type 2 diabetes. The decision gives Aspen access to Canada’s expanding market for GLP-1 medicines. However, regulatory approval…
Tag: Health Canada
-
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is gearing up to launch one of the world’s first generic semaglutide in Canada, capitalising on the recent loss of patent protection for Novo Nordisk’s blockbuster GLP‑1 weight‑loss injection. The move could be a pivotal moment for access and competition in an increasingly lucrative market. Canada’s early patent expiry of semaglutide has drawn global attention. Industry leaders see…